Abstract
Sensitizing Epidermal Growth Factor Receptor (EGFR) mutations confers a better prognosis and predicts a favorable response to treatment with EGFR tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC). We sought to determine the prognostic utility of a comprehensive panel of clinical, immune and biochemical markers in EGFR-mutant advanced NSCLC patients treated with first-line EGFR TKIs.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
